Skip to main content
OpenTrials
Completed

NCT Number: NCT04369807

Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection

A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Body Weight Coronaviridae Infections Coronavirus Infections Digestive System Diseases Fatty Liver Glucose Metabolism Disorders Hyperinsulinism Infections Insulin Resistance Liver Diseases Lung Diseases Metabolic Diseases Metabolic Syndrome Nidovirales Infections Non-alcoholic Fatty Liver Disease Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic Healthcare, London, United Kingdom

Loading trial locations.

About this study

To date, correctly, all of the Government's efforts have been dedicated to providing sufficient hospital space, and the appropriate equipment, for treating the most serious cases of COVID-19. Equally, enormous resource is being dedicated to developing technologies that determine who has the disease, and who has developed antibodies to it.

However, patients recovering from serious disease will also pose a huge, ongoing challenge. Not only are people with co-morbidities including underlying fatty liver disease, metabolic syndrome and diabetes at higher risk for complications with COVID-19; but patients discharged from hospital after severe COVID-19 are reported to have liver and kidney injuries, and impacts on pancreas and spleen. However, the extent of organ health/damage has not been mapped.

This is a prospective, longitudinal, observational cohort study looking at patients recovering from COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury. This proposed study aims to measure the prevalence of organ volume changes and damage in lungs, heart, kidney, liver, pancreas, spleen as assessed by MRI among those having recovered, or recovering, from the SARS-CoV-2 infection - participants will have a final MRI scan at 12 months. Assessing the severity and sequelae of COVID-19 in patients is crucial to enable global planning for health-care needs. The study includes up to 3 visits for MRI scans and blood tests over a 12 month period. All participants will receive standard-of-care by their healthcare provider/s.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female 18 years of age and older willing and able to give informed consent to participate in the study
  • Recent confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged 7 or more days from hospital).

Exclusion criteria

  • Symptoms of active respiratory viral infection:
  • high temperature (over 37.8C/100.04F)
  • cough (consistent for over an hour; 3 or more episodes in 24 hours)
  • The participant may not enter the study with any known contraindication to magnetic resonance imaging (including but not limited to pregnancy, a pacemaker or other metallic unfixed implanted device, metallic fragments, extensive tattoos, severe claustrophobia).
  • Any other cause, including a significant underlying disease or disorder which, in the opinion of the investigator, may put the participant at risk by participating in the study or limit the participant's ability to participate.

Treatment and study plan

Outpatient MRI

Diagnostic Test

Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.

There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications.

Other names: Outpatient blood tests for laboratory studies and genotyping, Outpatient measurements (height, weight, blood pressure), Online Questionnaires

Primary outcomes

  1. Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)

    Time frame: 12 Months

    In patients recovering from COVID-19 disease:

    Characterise using summary statistics the prevalence and severity of organ volume change and damage to heart, kidneys and liver

Secondary outcomes

  1. Characterise prevalence and severity of organ volume change and damage (lung, pancreas and spleen)

    Time frame: 12 Months

    In patients recovering from COVID-19 disease:

    To characterise using summary statistics the prevalence and severity of organ volume change and damage in lung, pancreas and spleen

  2. Change from Baseline in liver-specific biomarkers: volume, iron corrected T1(cT1), fat content and T2star

    Time frame: 6 Months

    In patients recovering from COVID-19 disease:

    Characterise liver damage as assessed by liver volume in liters, iron corrected T1 (cT1) in milliseconds, liver fat content as %, liver T2star in milliseconds (a correlate of liver iron content)

  3. Change from Baseline in organ-specific biomarkers characterising organ volume change in the heart and spleen along with organ volume and damage in the kidney, liver and pancreas assessed by volume, iron corrected T1 (cT1) and fat infiltration

    Time frame: 12 Months

    In patients recovering from COVID-19 disease:

    Characterise heart and spleen damage as assessed by liver volume in liters as well as kidney, liver and pancreas damage as assessed by volume in liters, iron corrected T1 (cT1) in milliseconds, fat infiltration as %, T2star in milliseconds (a correlate of liver iron content).

  4. Change in patient reported outcome measured by the Dyspnea-12 questionnaire

    Time frame: 12 Months

    In patients recovering from COVID-19 disease:

    Change in patient reported outcome measures collected to assess breathlessness and its effect on overall health and daily life assessed by Dyspnea-12. Each question is assigned a value between: none, mild, moderate and severe and is used to assess breathing characteristics.

  5. Change in patient reported outcome measured by the Saint George's Respiratory questionnaire (SGRQ)

    Time frame: 12 Months

    In patients recovering from COVID-19 disease:

    Change in patient reported outcome measures collected to assess breathlessness and its effect on overall health and daily life assessed by the St. George's Respiratory questionnaire. Each section comprises of questions in various formats allowing to assess which aspects of the illness cause the participant the most problems in daily life. There is no score on a scale to communicate the scale title.

  6. Change in patient reported outcome measured by the EQ-5D-5L questionnaire

    Time frame: 12 Months

    In patients recovering from COVID-19 disease:

    Change in patient reported outcome measures collected to assess breathlessness and its effect on overall health and daily life assessed by the EQ-5D-5L questionnaire. Two main sections provide the opportunity to capture statements best describing a participant's daily health and a scale form 0 to 100 capturing self-reported health stats. (100 being the best health imaginable and vice versa)

  7. Degree of change in liver MR-derived biomarkers

    Time frame: 12 Months

    In patients recovering from COVID-19 disease:

    Difference from Baseline in degree of change in liver MR-derived biomarkers with and without known genetic variants associated with liver disease (e.g., PNPLA3) using a paired t-test (or non-parametric alternative)

Sponsors and collaborators

Lead sponsor

Perspectum

Industry

Registry information

Acronym: COVERSCAN

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Apr 30, 2020
Registry last updated
Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.